Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies

Purpose of review The most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment of symptoms of schizophrenia and related conditions are summarized, including observed tolerability and reported side-effects. Recent findings Recent studies focused on patients with sub-acute psychotic syndromes of schizophrenia, clinical high-risk state for psychosis (CHR-P), or frequent cannabis users, as well as cognitive functioning in chronic schizophrenia. There is further, although not consistent evidence for cannabidiol-reducing positive symptoms, but not negative symptoms. Evidence for improvement of cognition was weaker, with one study reporting a worsening. Regarding side effects and tolerability, cannabidiol induced sedation in one study, with the other studies indicating good tolerability, even at high doses. Summary Recent clinical trials added further evidence for an antipsychotic potential of cannabidiol. In general, studies following trial designs as suggested by regulators in schizophrenia are needed in sufficient numbers to clarify the safety and efficacy of cannabidiol herein. In addition, such studies will further elucidate its ability to target specific aspects of the syndrome, such as negative or cognitive symptoms. Furthermore, aiming for an add-on treatment with cannabidiol will require further studies to identify potentially useful or even harmful combinations.
Source: Current Opinion in Psychiatry - Category: Psychiatry Tags: SCHIZOPHRENIA AND RELATED DISORDERS: Edited by Lynn E. DeLisi and Iris E.C. Sommer Source Type: research

Related Links:

Catatonia was first described by Karl Ludwig Kahlbaum in 1874, occurring in association with other psychiatric and medical disorders. However, in the nineteenth century the disorder was incorrectly classified as a subtype of schizophrenia. This misclassification persisted until the publication of DSM-5 in 2013 when important changes were incorporated. Although the etiology is unknown, disrupted gamma-aminobutyric acid has been proposed as the underlying pathophysiological mechanism. Key symptoms can be identified under 3 clinical domains: motor, speech, and behavioral. Benzodiazepines and electroconvulsive therapy are the ...
Source: Child and Adolescent Psychiatric Clinics of North America - Category: Psychiatry Authors: Source Type: research
American Journal of Psychiatry, Ahead of Print.
Source: American Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
AbstractSchizophrenia is among the most stigmatized mental illness. Adolescence may be a critical time to intervene, before stigmatizing attitudes have been solidified. As such, schools may be in a unique position to provide anti-stigma interventions to a large number of students. The aim of this paper was to review and critically analyze the most recent (2003-present) school-based schizophrenia stigma interventions, with seven studies identified. Studies were analyzed according to their intervention method, outcome measures, and experimental design. Substantial heterogeneity between studies precluded concrete conclusions ...
Source: Psychiatric Quarterly - Category: Psychiatry Source Type: research
Acase report inSchizophrenia Bulletin suggests that patients who are taking clozapine may be at risk of clozapine toxicity if they become infected with COVID-19. Clozapine is considered the best option for patients with treatment-resistant schizophrenia, but patients taking the medication are at heightened risk of a rare but serious condition known as neutropenia, which can increase risk of severe infections.In theSchizophrenia Bulletinreport, Thomas Cranshaw, M.B.B.S., and Thiyyancheri Harikumar, M.B.B.S., of Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust in England, described a 38-year-old man in an inpatie...
Source: Psychiatr News - Category: Psychiatry Tags: clozapine COVID-19 Schizophrenia Bulletin Thiyyancheri Harikumar Thomas Cranshaw toxicity Source Type: research
Authors: Jones MT, Strassnig MT, Harvey PD Abstract INTRODUCTION: While antipsychotics have been generally successful in treating psychosis in schizophrenia, there is a major treatment gap for negative symptoms and cognitive deficits. Given that these aspects of the disease contribute to poor functional outcomes independently of positive symptoms, treatments would have profound implications for quality of life. The 5-HT2A- receptor has been considered a potential target for interventions aimed at negative and cognitive symptoms and multiple antagonists and inverse agonists of this receptor have been tested. ARE...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
This study aims to analyze genome-wide the effect of SNPs on violence in schizophrenia. We...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
  Should people with mental illness have children? In today’s Not Crazy Podcast, Gabe and Lisa discuss their own reasons for not having kids, while also giving a platform to Amy Barnabi, a mother of two with bipolar disorder. Amy discusses her decision to have children and shares her experiences, joys and challenges thus far. What if you can’t be a good parent when your illness flares up? What if the child inherits your diagnosis? If you are a parent with mental illness, you’ve likely heard these questions. Tune in to hear these topics discussed (and much more!) on today’s podcast. (Transcript...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Bipolar Children and Teens Disorders Family General Interview Mental Health and Wellness Not Crazy Podcast Source Type: blogs
AbstractSchizophrenia (SZ) is a complex and severe psychiatric disorder, which has a global lifetime prevalence of 0.4% and a heritability of around 0.81. A number of epigenome-wide association studies (EWAS) have been carried out for SZ, with discordant results. The main aim of this study was to carry out an integrative in silico analysis of available genome-wide DNA methylation profiles in schizophrenia. In this work, an integration of multiple lines of evidence (top candidate genes from several EWAS and genome-wide expression and association data) was carried out, in order to identify top differentially methylated (DM) ...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
DiscussionThe negative association between negative symptom severity and parasympathetic activity was significant, which may inspire further research into the corresponding treatment, the mechanisms, and the use of HRV as an applicable biomarker for treatment response.
Source: Asia-Pacific Psychiatry - Category: Psychiatry Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractPatients with schizophrenia (SZ) have a high level of cardiovascular morbidity and some clinical symptoms of illness remain resistant to pharmacological approaches. A large number of studies support the effectiveness of physical activity (PA) in SZ. The aims of this trial is to assess the effects of a remote, web-based adapted PA program (e-APA) compared to a health education program (e-HE) on brain plasticity in SZ and healthy volunteers (HV) and on psychiatric, neurocognitive, circadian and physical variables. The study is an interventional, multicenter, randomized open-label trial. Forty-two SZ will be randomize...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Neuroscience Source Type: research
More News: Clinical Trials | Psychiatry | Schizophrenia | Study